Loading…
An in vitro comparison of commonly used topical glucocorticoid preparations
Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinop...
Saved in:
Published in: | Journal of allergy and clinical immunology 1999-09, Vol.104 (3), p.623-629 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03 |
---|---|
cites | cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03 |
container_end_page | 629 |
container_issue | 3 |
container_start_page | 623 |
container_title | Journal of allergy and clinical immunology |
container_volume | 104 |
creator | Stellato, Cristiana Atsuta, Jun Bickel, Carol A. Schleimer, Robert P. |
description | Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function.
Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B.
Methods: Cells were treated for 24 hours with increasing concentrations (range 10
–13 to 10
–6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry.
Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP ≅ TAA >> HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP >> BUD > TAA > HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive.
Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.) |
doi_str_mv | 10.1016/S0091-6749(99)70334-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70036184</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674999703349</els_id><sourcerecordid>70036184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMozjj6CEoXIrqonlx6yUqGwRsOuFDXIZMmEmmbmrQD8_ZmLqg7Nwk_-f6cw4fQKYZrDDi_eQXgOM0Lxi85vyqAUpbyPTTGwIs0L0m2j8Y_yAgdhfAJMdOSH6IRBlaSkpZj9DxtE9smS9t7lyjXdNLb4NrEmXVqXFuvkiHoKuldZ5Wsk496UE4531vlbJV0XseK7K1rwzE6MLIO-mR3T9D7_d3b7DGdvzw8zabzVGWU9GmFs4wpyjHOK8AFAQMEFkbxEkwhi8LkWmUSaE6pIQZyHU9NFKaMccbjwwRdbP_tvPsadOhFY4PSdS1b7YYgCohlXLIIZltQeReC10Z03jbSrwQGsbYoNhbFWpHgXGwsCh57Z7sBw6LR1Z_WVlsEzneADFGK8bJVNvxynJWMkIjdbjEdbSyt9iIoq1ulK-u16kXl7D-bfAMQSo57</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70036184</pqid></control><display><type>article</type><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><source>ScienceDirect Freedom Collection</source><creator>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</creator><creatorcontrib>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</creatorcontrib><description>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function.
Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B.
Methods: Cells were treated for 24 hours with increasing concentrations (range 10
–13 to 10
–6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry.
Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP ≅ TAA >> HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP >> BUD > TAA > HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive.
Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/S0091-6749(99)70334-9</identifier><identifier>PMID: 10482838</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Topical ; Adult ; allergy ; Anti-Inflammatory Agents - pharmacology ; basophil ; Basophils - cytology ; Basophils - drug effects ; Biological and medical sciences ; Cell Line ; Cell Survival - drug effects ; Cells, Cultured ; eosinophil ; Eosinophils - drug effects ; epithelial cells ; Glucocorticoids ; Glucocorticoids - pharmacology ; Histamine Release - drug effects ; Humans ; In Vitro Techniques ; Medical sciences ; Pharmacology. Drug treatments ; Respiratory system ; Vascular Cell Adhesion Molecule-1 - biosynthesis</subject><ispartof>Journal of allergy and clinical immunology, 1999-09, Vol.104 (3), p.623-629</ispartof><rights>1999 Mosby, Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</citedby><cites>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1948422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10482838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stellato, Cristiana</creatorcontrib><creatorcontrib>Atsuta, Jun</creatorcontrib><creatorcontrib>Bickel, Carol A.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function.
Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B.
Methods: Cells were treated for 24 hours with increasing concentrations (range 10
–13 to 10
–6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry.
Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP ≅ TAA >> HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP >> BUD > TAA > HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive.
Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</description><subject>Administration, Topical</subject><subject>Adult</subject><subject>allergy</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>basophil</subject><subject>Basophils - cytology</subject><subject>Basophils - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>eosinophil</subject><subject>Eosinophils - drug effects</subject><subject>epithelial cells</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - pharmacology</subject><subject>Histamine Release - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Vascular Cell Adhesion Molecule-1 - biosynthesis</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKxDAUhoMozjj6CEoXIrqonlx6yUqGwRsOuFDXIZMmEmmbmrQD8_ZmLqg7Nwk_-f6cw4fQKYZrDDi_eQXgOM0Lxi85vyqAUpbyPTTGwIs0L0m2j8Y_yAgdhfAJMdOSH6IRBlaSkpZj9DxtE9smS9t7lyjXdNLb4NrEmXVqXFuvkiHoKuldZ5Wsk496UE4531vlbJV0XseK7K1rwzE6MLIO-mR3T9D7_d3b7DGdvzw8zabzVGWU9GmFs4wpyjHOK8AFAQMEFkbxEkwhi8LkWmUSaE6pIQZyHU9NFKaMccbjwwRdbP_tvPsadOhFY4PSdS1b7YYgCohlXLIIZltQeReC10Z03jbSrwQGsbYoNhbFWpHgXGwsCh57Z7sBw6LR1Z_WVlsEzneADFGK8bJVNvxynJWMkIjdbjEdbSyt9iIoq1ulK-u16kXl7D-bfAMQSo57</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Stellato, Cristiana</creator><creator>Atsuta, Jun</creator><creator>Bickel, Carol A.</creator><creator>Schleimer, Robert P.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990901</creationdate><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><author>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Topical</topic><topic>Adult</topic><topic>allergy</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>basophil</topic><topic>Basophils - cytology</topic><topic>Basophils - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>eosinophil</topic><topic>Eosinophils - drug effects</topic><topic>epithelial cells</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - pharmacology</topic><topic>Histamine Release - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Vascular Cell Adhesion Molecule-1 - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stellato, Cristiana</creatorcontrib><creatorcontrib>Atsuta, Jun</creatorcontrib><creatorcontrib>Bickel, Carol A.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stellato, Cristiana</au><au>Atsuta, Jun</au><au>Bickel, Carol A.</au><au>Schleimer, Robert P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An in vitro comparison of commonly used topical glucocorticoid preparations</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>104</volume><issue>3</issue><spage>623</spage><epage>629</epage><pages>623-629</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function.
Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B.
Methods: Cells were treated for 24 hours with increasing concentrations (range 10
–13 to 10
–6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry.
Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP ≅ TAA >> HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP >> BUD > TAA > HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive.
Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>10482838</pmid><doi>10.1016/S0091-6749(99)70334-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-6749 |
ispartof | Journal of allergy and clinical immunology, 1999-09, Vol.104 (3), p.623-629 |
issn | 0091-6749 1097-6825 |
language | eng |
recordid | cdi_proquest_miscellaneous_70036184 |
source | ScienceDirect Freedom Collection |
subjects | Administration, Topical Adult allergy Anti-Inflammatory Agents - pharmacology basophil Basophils - cytology Basophils - drug effects Biological and medical sciences Cell Line Cell Survival - drug effects Cells, Cultured eosinophil Eosinophils - drug effects epithelial cells Glucocorticoids Glucocorticoids - pharmacology Histamine Release - drug effects Humans In Vitro Techniques Medical sciences Pharmacology. Drug treatments Respiratory system Vascular Cell Adhesion Molecule-1 - biosynthesis |
title | An in vitro comparison of commonly used topical glucocorticoid preparations |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20in%20vitro%20comparison%20of%20commonly%20used%20topical%20glucocorticoid%20preparations&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Stellato,%20Cristiana&rft.date=1999-09-01&rft.volume=104&rft.issue=3&rft.spage=623&rft.epage=629&rft.pages=623-629&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/S0091-6749(99)70334-9&rft_dat=%3Cproquest_cross%3E70036184%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70036184&rft_id=info:pmid/10482838&rfr_iscdi=true |